11th International Congress on Drug Therapy in HIV Infection, 11-15 November 2012, Glasgow

Poster

1 Impact of antiretroviral therapy (ART), viraemia and immunosuppression on lipid levels: the D:A:D Study. DA Kamara, C Sabin, P Reiss, M Rickenbach, C Smith, S De Wit, M Law, A Mocroft, C Pradier, JD Lundgren.
thistle presentation

XIX International AIDS Conference, Wash DC, July 2012

Oral Presentation

Trends over time in underlying causes of death in the D:A:D Study from 1999 to 2011. CJ Smith, L Ryom, R Weber, P Morlat, C Pradier, P Reiss, J Kowalska, N Friis-Møller, AN Phillips, CA Sabin, JD Lundgren for the D:A:D Study Group.
presentation

19th Conference on Retroviruses and Opportunistic Infections, Seattle, March 2012

Oral Presentations

1 Non-AIDS defining malignancies (NADM) and immunosuppression: The D:A:D study. Signe W. Worm, M Bower, P Reiss, A Grulich, E Fontas, F Bonnet, G Faetkenheuer, M Law, A Phillips, HJ Furrer, W El-Sadr, O Kirk, L Ryom, D Abrams, A D’Arminio Monforte, S De Wit, C Sabin, JD Lundgren on behalf of the D:A:D study group.
Presentation (197 kb)

Poster Presentations

1 Exposure to Antiretrovirals (ARVs) and the Risk of Renal Impairment among HIV+ Persons with Normal Baseline Renal Function: the D:A:D Study. L Ryom, A Mocroft, SW Worm,, DA Kamara, P Reiss, M Ross, C Fux, P Morlat, O Moranne, C Smith, O Kirk and JD Lundgren on behalf of the D:A:D study group.
Poster (105 kb)

2 Atazanavir (ATV)-Containing Antiretroviral Treatment is not Associated with an Increased Risk of Cardio- or Cerebro-Vascular Events (CVE) in the D:A:D Study. A d’Arminio Monforte, P Reiss, L Ryom, W El-Sadr, F Dabis, S De Wit, SW Worm, A Phillips, J Lundgren, and C Sabin.
Poster (101 kb)

3 Associations between Markers of Immunosuppression and the Risk of Cardiovascular Disease (CVD): the D:A:D Study C Sabin, SW Worm, M Law, W El-Sadr, P Reiss, M Bruyand, E Fontas, A d’Arminio Monforte, R Weber, O Kirk, S de Wit, JD Lundgren on behalf of the D:A:D Study Group.
Poster (202 kb)